Published in final edited form as:

Neurobiol Aging. 2010 August ; 31(8): 1481–1492. doi:10.1016/j.neurobiolaging.2010.03.016.

Integrating ADNI Results into Alzheimer's Disease Drug Development Programs

Jeffrey L. Cummings, MD

From the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is providing critical new information on biomarkers in cognitively normal elderly, persons with mild cognitive impairment (MCI), and patients with mild Alzheimer's disease (AD). The data provide insights into the progression of the pathology of AD over time, assist in understanding which biomarkers might be most useful in clinical trials, and facilitate development of disease-modifying treatments. ADNI results are intended to support new AD Treatments development; this paper considers how ADNI information can be integrated in AD drug development programs. Cerebrospinal fluid (CSF) amyloid beta protein (A β) measures can be used in Phase I studies to detect any short term effects on A β levels in the CSF. Phase II studies may benefit most from biomarker measures that can inform decisions about Phase III. CSF A β levels, CSF total tau and phosphotau measures, fluorodexoyglucose positron emission tomography (FDG PET), Pittsburgh Compound B (PIB) amyloid imaging, or magnetic resonance imaging (MRI) may be employed to select patient in enriched trials or as outcomes for specific disease-modifying interventions. Use of biomarkers may allow Phase II trials to be conducted more efficiently with smaller populations of patients or shorted treatment times. New drug applications (NDA) may include biomarker outcomes of phase III trials. ADNI patients are highly educated and are nearly all of Caucasian ethnicity limiting the generalizability of the results to other populations commonly included in global clinical trials. ADNI has inspired or collaborates with biomarker investigations worldwide and together these studies will provide biomarker information that can reduce development times and costs, improve drug safety, optimize drug efficacy, and bring new treatments to patients with or at risk for AD.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) began in 2004 as a five year research project to study the rate of change of cognition, function, brain structure and function, and biomarkers in 200 elderly controls, 400 subjects with mild cognitive impairment (MCI), and 200 with Alzheimer's disease (AD). The success of the program has led to its renewal and extension. ADNI is a unique public-private partnership involving the National Institute on Aging (NIA), academic medical centers and trial sites, and pharmaceutical companies. The over-arching goal of ADNI is to provide information and methods which will help lead to effective treatments and preventive interventions for AD (from the ADNI website

© 2010 Elsevier Inc. All rights reserved.

Contact: Jeffrey Cummings, MD, Mary S. Easton Center for Alzheimer's Disease Research, Suite 200, 10911 Weyburn Ave, Los Angeles, CA 90095-7226, T: 310-794-3665, F: 310-794-3148, jcummings@mednet.ucla.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosure: Dr. Cummings has no disclosures specific to the contents of this article.

www.adni-info.org). The specific aims of ADNI are: 1) develop improved methods, which will lead to uniform standards for acquiring longitudinal, multi-site magnetic resonance imaging (MRI) and positron emission tomography (PET) data on patients AD, MCI, and elderly controls; 2) acquire a generally accessible data repository, which describes longitudinal changes in brain structure and metabolism and in parallel, acquire clinical, cognitive and biomarker data for validation of imaging surrogates; and 3) determine those methods, which provide maximum power to determine treatment effects in trials involving these patient groups (from the ADNI grant proposal application; M Weiner, Principal Investigator).

To be made widely available to the world's population of AD patients, new treatments must meet efficacy, safety, and manufacturing standards specified by regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Pharmaceutical companies are the enterprises with sufficient resources to discover, develop, and market agents that can address the world's unmet health needs. Biomarker development such as that undertaken by ADNI must be integrated into drug development plans of pharmaceutical companies if they are to serve the stated purpose of facilitating the development of new treatments for AD. In addition, biomarkers are themselves subject to regulatory standards if they are to be part of a new drug application (NDA) as supporting data for the biological effect of the agent or, eventually, as surrogate markers in place of clinical outcomes in prevention trials. This paper addresses the role that ADNI data can play in a comprehensive drug development program. Issues hindering AD drug development that might be addressed within an ADNI-like framework also are described. Biomarker issues important in drug development and not addressed by ADNI are noted.

ROLES OF BIOMARKERS IN DRUG DEVELOPMENT

Biomarkers can play comprehensive roles in drug development including characterizing the disease state and its progression, demonstrating the pharmacokinetic effects of the body on the drug (absorption, distribution, metabolism, excretion, toxicity and blood-brain barrier penetration), proof of principle (POP)(for example, inhibition of cerebrospinal fluid [CSF] beta-site amyloid precursor protein cleavage enzyme [BACE]), dose selection, and efficacy (Figure 1). These data then facilitate corporate decision-making such as prioritizing compounds, optimizing agents with promising but insufficient effects or untoward off-target effects, or terminating a development program (Day, et al., 2009). The purpose of biomarkers is to improve drug safety, assist in drug candidate and dose choice, reduce development cycle times and costs, support the NDA, and improve the success rate of bringing compounds to market (Goodsaid, et al., 2008). Biomarkers will become more useful as the relationships between treatment and biomarkers outcomes are understood; this information will assist in optimizing compounds, choosing among compounds, and developing agents with different mechanisms of action but affecting overlapping disease pathways (Cummings, 2009a).

Biomarker development begins in the preclinical studies where the response of the marker to intervention can be assessed in animal models and methods and standards can be advanced for use in human studies (Kawarabayashi, et al., 2001; Lau, et al., 2008; Maeda, et al., 2007).

Biomarkers can assist in the development of both symptomatic agents and disease-modifying treatments for AD. Receptor occupancy studies, for example, can facilitate dose selection in the development of symptomatic agents. N-[C] methylpiperidin-4-yl acetate ([C]MP4A) PET demonstrates the inhibition of brain acetylcholinesterase (AChE) and informs the relationship between serum and brain AChE inhibition (Ota, et al., 2009). This information is useful in considering how best to optimize the efficacy of AChE- inhibitors. The greatest promise of biomarkers involves their application in the development of disease-modifying drugs. ADNI biomarkers are specifically aimed at this aspect of AD drug development. The biomarkers

chosen reflect measurable aspects of the AD disease process including amyloid beta protein (A β) metabolism (A β in the CSF), tau protein metabolism (total tau and hyperphosphorylated tau [p-tau] in the CSF), A β deposition (Pittsburgh Compound B [PIB] PET), synaptic function (fluorodeoxyglucose [FDG] PET), and neurodegeneration (MRI atrophy). They are designed to show the temporal course of these changes in patients with no disease, in patients with MCI (some of whom have early AD), and in subjects with mild AD dementia.

The predictive relationship between biomarker changes and clinical outcomes is critical to their successful utilization in AD drug development programs. This is not known for any AD-related biomarker. Preliminary correlations have been established (discussed below) for some clinical outcomes and some biomarkers; it is unknown if changes in a biomarker (such as reduced MRI ventricular enlargement with treatment) will correlate with reduced decline in cognition or function following treatment. There is no intervention in ADNI and the results of ADNI do not reveal relationships between treatment and biomarker changes. The ADNI dataset provides an important framework for selecting fit-for-purpose biomarkers most likely to predict clinical benefit.

Biomarkers will be incorporated into an NDA to support the candidate drug's mechanism of action, provide the basis for a claim for disease-modification, and differentiate the agent from symptomatic treatments or drugs with other mechanisms. The terminology that will be allowed by the FDA for these findings is unknown. Biomarker findings included in the labeling of the product inform prescribers, patients, caregivers, and pharmaceutical purchasing organizations of the effects of the drug. In the product label for glatiramer acetate (CopaxoneTM), a treatment for multiple sclerosis, for example, differing MRI rate in drug and placebo arm for the number of enhancing white matter lesions are shown (Cummings, 2009b). Similarly, ADNI-type biomarkers could be included in product labeling to provide information on rate of MRI atrophy, A β accumulation with PIB imaging, or changes in CSF A β or tau measures.

To support a claim that biomarker effects and clinical effects are mediated by similar underlying pathways the two must be correlated (Figure 2). Such a correlation does not prove a mechanistic relationship, but is necessary (although not sufficient) for the concept (Katz, 2004). Studying the relationships between biomarkers and clinical measures in the ADNI database is imperative as a means to understanding these potential correlations.

ADNI BIOMARKERS IN CLINICAL TRIALS

Following drug discovery, preclinical studies of pharmacokinetics and pharmacodynamics, lead optimization, and development of formulations acceptable for human consumption, candidate agents enter the steps of drug development (Prang, 2006; Rockwood and Gauthier (eds), 2006)(Figure 3). Phase 1 studies comprise first-in-human exposures beginning with single ascending doses and progressing to multiple ascending doses in small cohorts of subjects (6–10 per dose group). Subjects in these studies are typically normal healthy volunteers. An exception involves the development of immunotherapy where vaccinations and antibody infusions are given to patients with AD even in Phase 1 studies. Phase IIa studies seek proof-of-concept (POC) in studies with clinical outcomes and POP in studies with biomarker outcomes. These studies typically include 50–200 individuals per study arm of the intended treatment population (e.g., mild-to-moderate AD, MCI, etc). Phase IIb studies identify the dose or doses to be advanced to Phase III. Phase IIa and IIb may be combined in a multiple dose POC or POP study. Phase III studies include 200–600 patients per arm with the target disorder. Phase III studies of disease-modifying agents typically last 18 months. Clinical measures such as the Alzheimer's Disease Assessment Scale – cognitive portion (ADAS-cog), Clinical Dementia Rating (CDR), or the Alzheimer's Disease Cooperative Study Activities of Daily

Living (ADCS ADL) scale are the primary outcomes of Phase III studies. The clinical measures may be supported by biomarkers in the NDA.

Phase I

Biomarkers studied in ADNI can be used on all phases of drug development. Phase I studies are short in duration and use small sample sizes; they are not likely to show drug-placebo differences on structural neuroimaging measures. A β can be measured in CSF of normal persons and these measures may provide insight into the mechanistic impact of agents on A β metabolism (Galasko, et al., 2007; Siemers, et al., 2007). They are appropriate for Phase I studies.

Phase II

Biomarkers may facilitate Phase II studies substantially. Sponsors are faced with the conundrum of doing long, large Phase II studies to achieve POC or to do smaller shorter trials depending on biomarkers not proven to predict clinical success (Cummings, 2008). The former strategy has less risk but increases cost and expends valuable patent life of the compound; the latter approach is less expensive and faster but has greater risk for experiencing a negative outcome in Phase III. Phase III trials are much more expensive than Phase II trials (Prang, 2006) and decisions can be de-risked by generating as much information as possible in Phase II regarding whether to advance the compound. Biomarkers are attractive in this setting because they promise to show drug effects with fewer patients exposed for shorter periods of time than required to demonstrate drug-placebo differences on clinical measures.

Biomarkers with a high degree of diagnostic specificity can be used to enrich a trial population of MCI or putative AD patients with individuals very likely to harbor the AD process. ADNI studies have shown that a CSF profile of low A β 42 and elevated total-tau and p-tau characterizes AD; the p-tau/A β 42 ratio has a sensitivity of 91.1%, specificity of 71.2%, accuracy of 81.5%, positive predictive value of 77.3%, and negative predictive value of 88.1% (Shaw, et al., 2009). Similarly, a positive PIB scan identifies the presence of fibrillar amyloid plaques and demonstrates the presence of plaques in nearly all AD, 60% of MCI and 20–30% of cognitively normal elderly (Jack, et al., 2009). FDG PET shows reduced metabolism in the posterior cingulate, precuneus, parietotemporal regions, and frontal cortex of patients with AD (Langbaum, et al., 2009) and some patients with MCI. The ADNI sample demonstrates that medial temporal atrophy on MRI in patients with MCI predicts those MCI patients who will progress to AD dementia (McEvoy, et al., 2009; Misra, et al., 2009; Querbes, et al., 2009). Any of these biomarkers can be used to identify patients with the predementia form of MCI or to eliminate non-AD patients from AD dementia studies.

Data from ADNI studies have been used to determine sample sizes for clinical trials required to show a 20% or 25% reduction in disease progression (Table 1). Biomarkers (MRI, FDG PET) provide a numerical advantage over clinical measures in demonstrating a disease-modifying effect.

Caution must be exercised in extrapolating these calculations directly to clinical trials. The ADNI calculations are based on studying the rate or amount of change occurring in a structure in a given time (e.g., hippocampal change in 12 months) and calculating how many patients would be required to show a drug-placebo difference if the drug had a 20% or 25% effect. An agent, however, that decreased A β production by 25% might not have a 25% effect on MRI volumetrics since these are measures of neurodegeneration and the relationships between A β production and neurodegeneration are unknown. Power calculations for trials should allow for these uncertainties.

Biomarkers will be more useful in trials if they correlate with clinical outcomes. ADNI biomarkers data have been investigated from this perspective. In AD, rates of left and right hippocampal atrophy correlated with baseline CDR sum of the boxes (CDR-SB), (left 0.173, $p < 0.01$; right 0.181 $p < 0.01$) and change in CDR-SB (-0.174 , $p < 0.01$; 0.171 , $p < 0.01$) (Morra, et al., 2009). Temporal lobe atrophy assessed with tensor based morphometry (TBM) correlated with CDR-SB in AD and MCI and with the immediate and delayed recall scores of the logical memory tests of the Wechsler Memory Scale-Revised (Hua, et al., 2008a). MRI demonstrates a correlation between ventricular enlargement and CDR-SB (Jack, et al., 2009) and between ventricular enlargement and ADAS-cog scores (Evans, et al., 2009). TBM measures of ventricular expansion also correlated with CDR-SB ($p = 0.002$) (Hua, et al., 2008b). Structural Abnormality Index (STAND) scores reflecting the degree of AD-like anatomic features on MRI correlated with CDR-SB in MCI and AD (Vemuri, et al., 2009a). Mini-mental State Examination (MMSE) scores and ADAS-cog scores correlated with FDG-PET but not with PIB or CSF A β 42 measures (Jagust, et al., 2009; Landau, et al., 2009). These observations suggest that hippocampal atrophy changes measurably over time; ventricular enlargement may have the most robust correlations with commonly used clinical trial measures such as CDR-SB.

Correlations in the natural history of the disease do not necessarily predict linked change in response to therapy and measures that show little relationship to diagnosis or cognition might respond to therapeutic interventions. Serum A β 42, for example, does not distinguish AD from normal elderly but declined in patients treated with the gamma-secretase inhibitor LY-450139 (Fleisher, et al., 2008) suggesting that it might function as an outcome measure reflective of reduced A β 42 production.

Measures that are closely related to the mechanism of action of the drug are most likely to show a treatment effect. CSF A β measures have promise as outcomes of secretase inhibitors (Hussain, et al., 2007); CSF total tau and p-tau are most reflective of treatment mechanisms targeting neurofibrillary tangle formation (Tapiola, et al., 2009); FDG PET most closely reflects synaptic activity (Langbaum, et al., 2009); PIB measures fibrillary amyloid deposition (Ikonomovic, et al., 2008); and MRI measures neurodegeneration with loss of neurons and brain substance (Bobinski, et al., 2000). When choosing among biomarkers, fit-for-purpose decisions will include sensitivity, specificity, relationship to mechanism of action of the agent, and purpose of the biomarker in the trial (e.g. identify the optimal patients, validate the mechanism of action, demonstrate effects on a widely available tool such as MRI, etc).

Phase III

Phase III trials require clinical outcomes for the NDA and the sample sizes cannot be reduced using biomarkers. Moreover, larger samples are needed to provide the necessary exposures to detect safety or tolerability issues associated with the trial agent. Biomarkers, however, are required to support a disease-modifying type claim unless randomized start or randomized withdrawal trial designs are utilized to demonstrate disease modification (Katz, 2004). Biomarkers will be included as part of a disease-modifying NDA in most cases.

Enrichment strategies such as those discussed above may be used in Phase III trials to insure the presence of the AD process in the trial population. If enrichment is used in trials submitted as part of the NDA, the labeling will reflect this decision. The indication language will specify the use of the agent in the enriched population. Thus, the indication might be for patients with a high CSF p-tau /A β 42 ratio, positive PIB imaging, or medial temporal atrophy, depending on the biomarker chosen for enrichment.

MRI is the biomarker of choice for either enrichment or as an outcome marker in Phase III trials. ADNI has demonstrated the feasibility of multicenter collection of MR images and ADNI

investigators have developed the technology for phantom-based calibration, automatic image quality assessment, and automated segmentation of subregions such as the hippocampus (Chupin, et al., 2009; Clarkson, et al., 2009; Mortamet, et al., 2009). MRI technology is widely available, making it possible to obtain scans on all cooperative trial subjects and avoiding issues that may confound analyses when nested subgroups of subjects are assessed with biomarkers and attempts made to generalize the findings.

Primary Prevention Trials

Prevention trials are aimed at developing medications that can be administered to cognitively normal individuals to forestall or prevent the occurrence of AD (Andrieu, et al., 2009). No FDA-approved preventive therapies for AD are available currently. Although AD is a common disorder, it is rare in any limited group of elderly persons followed for a relatively short period of time. Demonstrating a drug-placebo difference in a clinical trial depends on having enough patients who decline cognitively or progress to a defined state (MCI or AD) in the placebo group to observe a treatment benefit in the active therapy group. With regard to AD, any aged group will be comprised of three subpopulations: 1) persons who will never get AD, 2) persons who have risk factors and may eventually develop AD, 3) persons who have AD established in the brain but are still cognitively normal (Cummings, et al., 2007). Epidemiologic factors can construct populations of those in the 2nd group; biomarkers are most useful for identifying those in the 3rd. To the extent possible those in the first group should not be exposed to possibly harmful medications. PIB imaging and CSF A β measures identify patients who are cognitively normal and who have evidence of AD pathology in the brain (Jack, et al., 2009; Shaw, et al., 2009).

Outcome measures for prevention trials could include clinical decline, development of MCI or AD, or progression on a biomarker. If a biomarker is proposed as a primary outcome, it must serve as a surrogate for clinical measures and known to predict clinical outcomes. Surrogate validation requires that the biomarker predict the clinical outcome across several trials and across several classes of relevant agents (Cummings, 2009a). Drugs can be approved by the FDA on the basis of effects on an unvalidated surrogate if the biomarker is relatively likely to predict clinical outcomes, the predicted effect is considered very important (delaying cognitive decline), and there are few or no other treatment options (Katz, 2004). If a drug is approved on the basis of an unvalidated surrogate, the sponsor may be required to conduct post-approval studies to demonstrate the link between the biomarker and the clinical benefit. Several ADNI biomarkers could serve as outcomes in prevention trials including MRI atrophy, CSF t-tau or p-tau, p-tau/A β 42 ratio, PIB imaging or FDG PET. None are validated surrogates but might qualify as unvalidated surrogates or could serve as key secondary outcomes in trials using clinical measures as primary outcomes.

ADNI CLINICAL SAMPLE: IMPLICATIONS FOR CLINICAL TRIALS

Demographic Features

Table 2 summarizes several important clinical features of the ADNI sample (Petersen, et al., 2009). Notably, the sample is very well educated with educational levels of 14.7 – 16 years indicating that most subjects had completed several years of college. Patients with higher education levels tend to have later onset of AD and faster progression after onset (Musicco, et al., 2009). This high level of education may complicate extrapolating some results to other trials, particularly international trials which tend to include more persons with low educational levels. Similarly, most trials have more women than men (Schneider and Sano, 2009), while the ADNI cohort has the reverse (% female ranging from 35.4 – 48). This might affect the generalization of some aspects of ADNI.

Clinical Trial Groups

ADNI includes three groups: cognitively normal controls, patients with MCI, and patients with mild AD. The inclusion and exclusion features for the groups are given in Table 3. Data from 11 recently completed and 12 on-going 18-month AD trials were recently reviewed by Schneider and Sano (Schneider and Sano, 2009). They reviewed the MMSE range, mean age, % female, and educational level of completed trials and the MMSE range of the on-going trials. Two of the 23 trials reviewed had MMSE ranges that mimicked those of the ADNI protocol (2 completed tarenflurbil trials). All of the other trials included patients with mild-to-moderate AD. The ADNI cohort provides data on more mild AD patients and anticipates the likely inclusion of more mild patients in clinical trials. Extrapolating biomarker data from ADNI to typical protocols including mild-to-moderate AD (typically an MMSE range of 16–26) is difficult; patients with more severe disease tend to progress more rapidly and may have different biomarker-clinical relationships (Ito, et al., 2009).

The cognitively normal group of ADNI showed almost no change in a 12-month period (Petersen, et al., 2009). Observed changes were MMSE 0.0 ± 1.4 , ADAS-cog -0.5 ± 3 , and CDR-SB 0.1 ± 0.3 . This indicates that an enrichment strategy will be necessary for prevention trials to have enough decline in the placebo group that a treatment-related benefit can be observed. The biomarker features of such an enriched group will require study to inform future trials. Enrichment alternatives include identifying persons with normal cognition and medial temporal atrophy, positive amyloid imaging, low CSF A β , declining cognition on sequential assessment, older age, family history of dementia or AD, predisposing genotype (e.g., ApoE-4 carriers), or demographic risk factors (e.g. low education level, small head size, history of midlife hypertension, history of hypercholesterolemia) (Cummings, et al., 2007).

MCI

MCI is a syndrome of variable etiology and outcome. Persons with MCI may recover normal cognition, remain in the MCI state, progress to AD type dementia, or progress to a non-AD dementia (Matthews, et al., 2008). Most but not all studies report that the prevalence of predementia AD is higher among patients with amnesic type of MCI (Yaffe, et al., 2006), but approximately 30% of patients presenting with amnesic MCI have non-AD pathology as the primary diagnosis at autopsy (Jicha, et al., 2006). New therapies for AD are focused on aspects of AD molecular biology and the AD substrate is required for their proposed mechanism of action. Biomarkers are an optimal means for identifying MCI patients whose cognitive decline reflects the presence of underlying AD. ADNI biomarkers that identify which patients with MCI have very early AD are most useful to drug development efforts. Cortical thickness mapping (Querbes, et al., 2009) and regional atrophy measures (McEvoy, et al., 2009) predict progression from MCI to AD type dementia and could be used to enrich MCI trial populations with MCI of the AD type. Likewise, FDG PET, PIB imaging and CSF A β and tau measures can identify MCI patients with early AD.

The combination of a clinical syndrome of amnesic MCI and a biomarker indicative of AD fulfills the main criteria for the definition of AD proffered by Dubois et al (Dubois, et al., 2007). This definition of AD embraces both the predementia and dementia phases of the illness and provides a means of defining a trial population of AD patients who are in the most mild stage of the disease prior to the occurrence of dementia.

The clinical definition of MCI also bears on the likelihood of evolution to AD dementia (Matthews, et al., 2008). The definition of MCI used to define the ADNI cohort differs from the definition of MCI developed by Petersen et al (Petersen, et al., 2001; Petersen, et al., 1999). Table 4 summarizes the differences between the two definitional approaches to MCI. The definition employed in the ADNI MCI population is more defined operationally with

MMSE score ranges and thresholds for neuropsychological assessments. Patients with more than mild depression or more than minimal vascular symptoms are excluded. These differences will affect the composition of the trial population and the ADNI biomarker findings will apply most readily to MCI populations using the same MCI definition. Minor differences in MCI definitions have substantial effects in clinical trials as evidenced by the markedly different percentages of apolipoprotein e4 carriers across MCI trials (Jelic, et al., 2006). Results must be extrapolated from trial to trial with caution; and ADNI results also must be generalized with careful consideration of the sample selection criteria.

QUALIFICATION OF BIOMARKERS

Biomarkers must go through a qualification process prior to inclusion in regulatory-quality clinical trials. The FDA has specified the qualification process (Goodsaid and Frueh, 2007) and the steps of the process are shown in Figure 4. Investigation of biomarkers for AD by ADNI provides a platform on which to build the qualification process and establish that a specific biomarker is fit-for-purpose for a specific trial and could be included in an NDA.

COMMENT

ADNI has led to remarkable progress in understanding biomarkers in AD and MCI. The course of biomarker change over time is being mapped, the relationship among biomarkers is being defined, and the associations between biomarkers and clinical changes are being demonstrated. Biomarkers are positioned to play a larger role in drug development based on ADNI data. Phase II studies may be shortened, Phase III studies may include biomarkers as part of a disease-modifying NDA, and biomarkers may play key roles in primary prevention trials. Biomarkers will help de-risk Phase III decisions, reduce drug development times and costs, improve safety, and speed the development of urgently needed new treatments.

Review of the ADNI studies reveal several unmet needs in the realm of biomarker development. Most critical are more data on the link between clinical and biomarkers changes in response to treatment. Only a few studies including both outcomes have been reported (Fox, et al., 2005; Gilman, et al., 2005; Lannfelt, et al., 2008; Salloway, et al., 2009), and only the repeated use of biomarkers in studies of drugs affecting AD pathways will eventually inform the use of these measures as predictors of clinical benefit (Cummings, 2009a). ADNI is a noninterventive natural history observational study and cannot contribute to this aspect of biomarker development.

Another unmet need in biomarker development pertains to measures of target engagement or drug activity. ADNI biomarkers characterize the natural history of AD. Drug development has been accelerated by combining a target engagement biomarker with natural history outcomes (Wagner, 2008). For example, in the development of statins, cholesterol lowering can be measured directly as an immediate drug effect and linked to patient outcomes such as death, myocardial infarction, or stroke. Pharmaceutical development in AD would be facilitated by development of drug activity biomarkers that directly measure the effect of the candidate treatment on the target pathways (e.g., A β production, inflammation, oxidation) and including such measures together with natural history biomarkers and clinical outcomes in clinical trials. Biomarkers of the drug effect should be sought and characterized during the preclinical phase of drug development and extended into the clinical phases of the development program (Choi, et al., 2009; Dubois, et al., 2010; Higuchi, et al., 2010).

The populations studied by ADNI anticipate the need to treat patients early in the course of AD and include patients with predementia syndromes and mild dementia. Most AD drugs are tested in patients with mild-to-moderate AD with MMSE scores in the 16–26 range. ADNI

data apply only to the more mild end of this range of severity. Biomarker data are needed on patients with more severe disease to assist drug development in this broader AD population.

Clinical trials are increasingly global enterprises. While the US conducts more clinical trials than any other single country, collectively more trials are conducted outside the US than in the US (Glickman, et al., 2009). Ex-US populations are often more poorly educated and less likely to be Caucasian than the ADNI cohort. The very high educational level of ADNI participants and the low rate of inclusion of non-White subjects limit the generalizability of the clinical and biomarker findings. The global biomarker interest inspired in part by ADNI will assist in characterizing persons with a broader range of educational levels and ethnic backgrounds. Among these world-wide studies are the European ADNI (Buerger, et al., 2009; Frisoni, et al., 2008); the AddNeuroMed study (Lovestone, et al., 2009); the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Aging (Ellis, et al., 2009); the Swedish Brain Power Initiative; and similar studies in Japan, Korea, and China (Miller, 2009).

Together with data from international collaborators, ADNI biomarker data provide information that is increasingly critical to the successful development of new treatments for AD, new therapies to slow the progression of MCI to AD dementia, and agents to prevent cognitive decline in the elderly. Ultimately, ADNI and related biomarkers promise to reduce drug development times, increase success rates, reduce costs, de-risk trials using clinical outcomes, and hasten the development of new treatments for AD.

Acknowledgments

Dr. Cummings is supported by the Sidell-Kagan Foundation, the Jim Easton Gift, a California Alzheimer's Disease Center grant, and an NIA Alzheimer's Disease Research Center grant (P50 AG16570).

References

- Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. *J Alzheimers Dis* 2009;16:235–270. [PubMed: 19221415]
- Association, AP. *Diagnostic and Statistical Manual of Mental Disorders (DSM)*. Washington, DC: American Psychiatric Press; 1994.
- Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. *Neuroscience* 2000;95:721–725. [PubMed: 10670438]
- Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). *Exp Gerontol* 2009;44:579–585. [PubMed: 19539742]
- Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. *J Nucl Med* 2009;50:1887–1894. [PubMed: 19837759]
- Chupin M, Gerardin E, Cuingnet R, Boutet C, Lemieux L, Lehericy S, Benali H, Garnero L, Colliot O. Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. *Hippocampus* 2009;19:579–587. [PubMed: 19437497]
- Clarkson MJ, Ourselin S, Nielsen C, Leung KK, Barnes J, Whitwell JL, Gunter JL, Hill DL, Weiner MW, Jack CR Jr, Fox NC. Comparison of phantom and registration scaling corrections using the ADNI cohort. *Neuroimage* 2009;47:1506–1513. [PubMed: 19477282]

- Cummings JL. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. *Alzheimers Dement* 2009a; 5:108–113. [PubMed: 19328437]
- Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. *Alzheimers Dement* 2009b;5:406–418. [PubMed: 19751920]
- Cummings JL. Optimizing phase II of drug development for disease-modifying compounds. *Alzheimers Dement* 2008;4:S15–S20. [PubMed: 18631992]
- Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. *Neurology* 2007;69:1622–1634. [PubMed: 17938373]
- Day M, Rutkowski JL, Feuerstein GZ. Translational medicine-a paradigm shift in modern drug discovery and development: the role of biomarkers. *Adv Exp Med Biol* 2009;655:1–12. [PubMed: 20047030]
- Dubois A, Herard AS, Delatour B, Hantraye P, Bonvento G, Dhenain M, Delzescaux T. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. *Neuroimage*. 2010
- Dubois B, Jacova J, DeKosky J, Barberger-Gateau P, Cummings JL, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *The Lancet Neurology* 2007;6:734–746.
- Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szeoke C, Taddei K, Villemagne V, Woodward M, Ames D. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. *Int Psychogeriatr* 2009;21:672–687. [PubMed: 19470201]
- Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC. Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. *Eur Radiol*. 2009
- Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. *Arch Neurol* 2008;65:1031–1038. [PubMed: 18695053]
- Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. *Neurology* 2005;64:1563–1572. [PubMed: 15883317]
- Frisoni GB, Henneman WJ, Weiner MW, Scheltens P, Vellas B, Reynish E, Hudecova J, Hampel H, Burger K, Blennow K, Waldemar G, Johannsen P, Wahlund LO, Zito G, Rossini PM, Winblad B, Barkhof F. The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. *Alzheimers Dement* 2008;4:255–264. [PubMed: 18631976]
- Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. *Alzheimer Dis Assoc Disord* 2007;21:292–299. [PubMed: 18090435]
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* 2005;64:1553–1562. [PubMed: 15883316]
- Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med* 2009;360:816–823. [PubMed: 19228627]
- Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. *AAPS J* 2007;9:E105–E108. [PubMed: 17408233]
- Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. *Toxicology* 2008;245:219–223. [PubMed: 18280028]
- Higuchi M, Maeda J, Ji B, Maruyama M, Okauchi T, Tokunaga M, Ono M, Suhara T. In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from

neuroimaging research in humans and rodent models. *Biochim Biophys Acta* 2010;1802:373–388. [PubMed: 20060898]

- Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, Jack CR Jr, Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Thompson PM. Alzheimer's Disease Neuroimaging I 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. *Neuroimage* 2008b;41:19–34. [PubMed: 18378167]
- Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR Jr, Weiner MW, Thompson PM. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. *Neuroimage* 2008a;43:458–469. [PubMed: 18691658]
- Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. *J Neurochem* 2007;100:802–809. [PubMed: 17156133]
- Ikonomic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolkowski S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain* 2008;131:1630–1645. [PubMed: 18339640]
- Ito K, Ahadiet S, Corrigan B, French J, Fullerton T, Tensfeldt T. Disease progression meta-analysis model in Alzheimer's disease. *Alzheimers Dement*. 2009
- Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. *Brain* 2009;132:1355–1365. [PubMed: 19339253]
- Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA. Relationships between biomarkers in aging and dementia. *Neurology* 2009;73:1193–1199. [PubMed: 19822868]
- Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. *J Neurol Neurosurg Psychiatry* 2006;77:429–438. [PubMed: 16306154]
- Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. *Arch Neurol* 2006;63:674–681. [PubMed: 16682537]
- Katz R. Biomarkers and surrogate markers: an FDA perspective. *NeuroRx* 2004;1:189–195. [PubMed: 15717019]
- Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. *J Neurosci* 2001;21:372–381. [PubMed: 11160418]
- Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. *Neurobiol Aging*. 2009
- Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Neuroimage* 2009;45:1107–1116. [PubMed: 19349228]
- Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurol* 2008;7:779–786. [PubMed: 18672400]
- Lau JC, Lerch JP, Sled JG, Henkelman RM, Evans AC, Bedell BJ. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. *Neuroimage* 2008;42:19–27. [PubMed: 18547819]

- Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund LO, Ward M. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. *Ann N Y Acad Sci* 2009;1180:36–46. [PubMed: 19906259]
- Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci* 2007;27:10957–10968. [PubMed: 17928437]
- Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? *J Am Geriatr Soc* 2008;56:1424–1433. [PubMed: 18662209]
- McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr, Holland D, Karow DS, Pung CJ, Brewer JB, Dale AM. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. *Radiology* 2009;251:195–205. [PubMed: 19201945]
- Miller G. Alzheimer's biomarker initiative hits its stride. *Science* 2009;326:386–389. [PubMed: 19833956]
- Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. *Neuroimage* 2009;44:1415–1422. [PubMed: 19027862]
- Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Toga AW, Jack CR Jr, Schuff N, Weiner MW, Thompson PM. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. *Neuroimage* 2009;45:S3–S15. [PubMed: 19041724]
- Mortamet B, Bernstein MA, Jack CR Jr, Gunter JL, Ward C, Britson PJ, Meuli R, Thiran JP, Krueger G. Automatic quality assessment in structural brain magnetic resonance imaging. *Magn Reson Med* 2009;62:365–372. [PubMed: 19526493]
- Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, Spalletta G, di Iulio F, Pettenati C, Cravello L, Caltagirone C. Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors. *J Neurol* 2009;256:1288–1295. [PubMed: 19353221]
- Ota T, Shinotoh H, Fukushi K, Kikuchi T, Sato K, Tanaka N, Shimada H, Hirano S, Miyoshi M, Arai H, Suhara T, Irie T. Estimation of Plasma IC50 of Donepezil for Cerebral Acetylcholinesterase Inhibition in Patients With Alzheimer Disease Using Positron Emission Tomography. *Clin Neuropharmacol*. 2009
- Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI). Clinical characterization. *Neurology*. 2009
- Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;58:1985–1992. [PubMed: 11735772]
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 1999;56:303–308. [PubMed: 10190820]
- Prang, H. Drug discovery and development. New York: Churchill Livingstone; 2006.
- Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, Puel M, Berry I, Fort JC, Celsis P. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. *Brain* 2009;132:2036–2047. [PubMed: 19439419]
- Rockwood, K.; Gauthier, S., editors. Trial designs and outcomes in dementia therapeutic research. London: Taylor and Francis; 2006.
- Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology* 2009;73:2061–2070. [PubMed: 19923550]
- Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. *Alzheimers Dement* 2009;5:388–397. [PubMed: 19751918]

- Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol* 2009;65:403–413. [PubMed: 19296504]
- Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. *Clin Neuropharmacol* 2007;30:317–325. [PubMed: 18090456]
- Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Arch Neurol* 2009;66:382–389. [PubMed: 19273758]
- Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. *Neurology* 2009a;73:287–293. [PubMed: 19636048]
- Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. *Annu Rev Pharmacol Toxicol* 2008;48:631–651. [PubMed: 17937595]
- Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. *Dement Geriatr Cogn Disord* 2006;22:312–319. [PubMed: 16940725]

Figure 1.
Role of biomarkers in AD drug development.

Figure 2.
Relationship of clinical outcomes and biomarkers in a clinical trial of an AD disease-modifying agent.

Figure 3.

AD drug development. Black arrows show the phases of drug development; the brick-colored arrows show the ADNI biomarkers that could be used in that stage. A β – amyloid beta protein; CSF – cerebrospinal fluid; FDG – fluorodeoxyglucose; MRI – magnetic resonance imaging; PET – positron emission tomography; PIB- Pittsburgh Compound B amyloid imaging

Figure 4. Steps in the process of biomarker qualification as specified by the FDA (Goodsaid and Frueh, 2007).

Table 1

Sample size calculations based on ADNI data for patients with AD.

Technique and Reference	Structure or Test	N Required to Show 25% Disease Slowing	N Required to Show 20% Disease Slowing
TBM (Hua et al, 2009)	Temporal lobe	48 (80% power); 64 (90% power)	
	ADAS-cog	619 (80% power); 828 (90% power)	
	CDR-SB	408 (80% power); 546 (90% power)	
MRI (Holland et al, 2009)	Entorhinal cortex	52–83 (confidence interval for 80% power)	
	Inferior temporal cortex	92–153	
	Hippocampus	91–158	
	Whole brain	139–271	
	Ventricles	168–371	
	ADAS-cog	192–457	
	CDR-SB	165–365	
MRI (Schuff, 2009)	MRI hippocampal volume (2 scans, 0–6 m)	462 (90% power)	
	2 scans (0–12 m)	252	
	3 scans (0–6–12 m)	255	
	3 scans + ApoE-4	196	
	ADAS-cog (0–6 m)	745	
	ADAS-cog (0–12 m)	814	
	ADAS-cog (0–6–12)	569	
FDG PET (Landau, 2009)	FDG-ROIs (scans at 0–12 m)	180	
	ADAS-cog	300	
MRI (Nestor, 2008)	Ventricular volume (all AD); 6 months		342
	Ventricular volume (AD without ApoE-4); 6 months		468
	Ventricular volume (AD without ApoE-4); 6 months		257
	ADAS-cog (all AD); 6 months		1607
	ADAS-cog (AD without ApoE-4); 6 months		2100
	ADAS-cog (AD with ApoE-4); 6 months		1370

ADAS-cog – Alzheimer's Disease Assessment Scale cognitive portion; Apo-E – apolipoprotein E; CDR-SB – Clinical Dementia Rating – Sum of the Boxes; FDG-PET – fluorodeoxyglucose positron emission tomography; ROIs- regions of interest; TBM – tensor based morphometry

Table 2

Demographic features of the ADNI sample (Petersen, et al., 2009).

Characteristic	Cognitively Normal Controls	MCI	AD
Number	229	398	192
Age, years (mean, SD)	75.8 +/- 5.0	74.7 +/-7.4	75.3 +/- 7.5
Education (mean, SD)	16 +/- 2.9	15.7 +/-3.0	14.7+/-3.1
% female	48	35.4	47.4
ApoE-e4 carrier	26.6	53.3	66.1
White	90.8	90.5	92.2

ApoE-e4- apolipoprotein epsilon 4; SD – standard deviation

Table 3

Characteristics of the patient groups included in the ADNI protocol.

Trial Feature	Normal Controls	MCI	Mild AD
Number	200	400	200
MMSE score	24–30	24–30	20–26
CDR	0; Memory Box score must be 0	0.5; Memory Box score must be at least 0.5	0.5 or 1
Memory complaint		Memory complaint by subject or study partner that is verified by a study partner	Memory complaint by subject or study partner that is verified by a study partner
Memory function	Normal memory function documented by scoring at specific cutoffs on the Logical Memory II subscale (delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25): a) more than or equal to 9 for 16 or more years of education, b) more than or equal to 5 for 8–15 years of education, c) more than or equal to 3 for 0–7 years of education	Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale– Revised (the maximum score is 25): a) less than or equal to 8 for 16 or more years of education, b) less than or equal to 4 for 8–15 years of education, c) less than or equal to 2 for 0–7 years of education	Same as MCI
General cognition	Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living	General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit	NINCDS/ADRDA criteria for probable AD
Modified Hachinski Ischemia Scale Score	≤ 4	≤ 4	≤ 4
Geriatric Depression Scale Score	< 6	< 6	< 6
Education	Completed 6 grades of education (or had a good work history sufficient to exclude mental retardation)	Completed 6 grades of education (or had a good work history sufficient to exclude mental retardation)	Completed 6 grades of education (or had a good work history sufficient to exclude mental retardation)

NINCDS/ADRDA – National Institute of Neurologic and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association

Table 4

MCI as defined by ADNI and as defined by Petersen et al (Petersen, et al., 2001; Petersen, et al., 1999).

Clinical Feature	Petersen MCI	ADNI MCI
MMSE score	Not specified	24–30
CDR	Not specified	0.5; Memory Box score must be at least 0.5
Memory complaint	Memory complaint documented by the patient and collateral source	Memory complaint by subject or study partner that is verified by a study partner
Memory function	Memory impaired for age and education	Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale- Revised (the maximum score is 25): a) less than or equal to 8 for 16 or more years of education, b) less than or equal to 4 for 8–15 years of education, c) less than or equal to 2 for 0–7 years of education
General cognition	Relatively normal; does not meet DSM-IV criteria for dementia	General cognition and functional performance sufficiently preserved such that a diagnosis of AD cannot be made by the site physician at the time of the screening visit
Modified Hachinski Ischemia Scale Score	Not specified	≤ 4
Geriatric Depression Scale Score	Not specified	< 6
Education	Not specified	Completed 6 grades of education (or had a good work history sufficient to exclude mental retardation)

DSM-IV – Diagnostic and Statistical Manual of Mental Disorders, 4th edition (Association, 1994)